Two new indications of AstraZeneca (AZN.US) monoclonal antibody launched in China

The Zhitong Finance App learned that on August 17, AstraZeneca (AZN.US) announced the official launch of tezelizumab injections in China. Tezelizumab is a biologic agent that treats severe asthma and breaks through phenotypic and biomarker level limits, and targets thymic stromal lymphopoietin (TSLP).

In March 2026, tezerizumab was approved in China based on the positive results of two phase 3 clinical studies of DIRECTION and WAYPOINT: for maintenance treatment of severe asthma in adults and adolescents aged 12 and above; this product is used in combination with nasal glucocorticoids to treat adult patients with chronic sinusitis with nasal polyps (CRSwnP) whose disease cannot be adequately controlled by systemic glucocorticoids and/or surgery.

Tezeliumab is a human monoclonal antibody developed by AstraZeneca in collaboration with Amgen, which can inhibit the activity of TSLP. TSLP is a key epithelial cytokine upstream of multiple inflammatory cascades and plays a central role in the initiation and continuation of allergic, eosinophilic, and epithelial-driven inflammation associated with severe asthma, chronic sinusitis with nasal polyps, and other inflammatory diseases.